2023-09411. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

    DATES:

    Submit written comments (including recommendations) on the collection of information by June 2, 2023.

    ADDRESSES:

    To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/​public/​do/​PRAMain. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0606. Also include the FDA docket number found in brackets in the heading of this document.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

    Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements—21 CFR Part 111

    OMB Control Number 0910–0606—Extension

    The Dietary Supplement Health and Education Act (Pub. L. 103–417) added section 402(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 342(g)), which provides, in part, that the Secretary of Health and Human Services may, by regulation, prescribe good manufacturing practice for dietary supplements. Section 402(g) of the FD&C Act also stipulates that such regulations will be modeled after Current Good Manufacturing Practice (CGMP) regulations for food and may not impose standards for which there are no current, and generally available, analytical methodology. Section 402(g)(1) of the FD&C Act states that a dietary supplement is adulterated if it has been prepared, packed, or held under conditions that do not meet current good manufacturing practice regulations.

    Accordingly, we have issued regulations in part 111 (21 CFR part 111) establishing minimum CGMP requirements pertaining to the manufacturing, packaging, labeling, or holding of dietary supplements to ensure their quality. Included among the requirements is recordkeeping, documenting, planning, control, and improvement processes of a quality control system. Implementation of these processes in a manufacturing operation serves as the backbone to CGMP. The records must show what is being manufactured and whether the controls in place ensure the product's identity, purity, strength, and composition and that limits on contaminants and measures to prevent adulteration are effective. Further, records must show whether and what deviations from control processes occurred, facilitate evaluation and corrective action concerning these deviations (including, where necessary, whether associated batches of product should be recalled from the marketplace), and enable a manufacturer to assure that the corrective action was effective. We believe the regulations in part 111 establish the minimum manufacturing practices necessary to ensure that dietary supplements are manufactured, packaged, labeled, or held in a manner Start Printed Page 27899 that will ensure the quality of the dietary supplements during manufacturing, packaging, labeling, or holding operations.

    Specifically, the recordkeeping requirements of the regulations in part 111 include establishing written procedures and maintaining records pertaining to: (1) personnel; (2) sanitation; (3) calibration of instruments and controls; (4) calibration, inspection, or checks of automated, mechanical, or electronic equipment; (5) maintaining, cleaning, and sanitizing equipment and utensils and other contact surfaces; (6) water used that may become a component of the dietary supplement; (7) production and process controls; (8) quality control; (9) components, packaging, labels, and product received for packaging and labeling; (10) master manufacturing and batch production; (11) laboratory operations; (12) manufacturing operations; (13) packaging and labeling operations; (14) holding and distributing operations; (15) returned dietary supplements; and (16) product complaints.

    Section 111.75(a)(1) (21 CFR 111.75(a)(1)) reflects FDA's determination that manufacturers that test or examine 100 percent of the incoming dietary ingredients for identity can be assured of the identity of the ingredient. However, we recognize that it may be possible for a manufacturer to demonstrate, through various methods and processes in use over time for its particular operation, that a system of less than 100 percent identity testing would result in no material diminution of assurance of the identity of the dietary ingredient as compared to the assurance provided by 100 percent identity testing. Section 111.75(a)(1) provides an opportunity for a manufacturer to make such a showing and reduce the frequency of identity testing of components that are dietary ingredients from 100 percent to some lower frequency. Section 111.75(a)(1) also sets forth the information a manufacturer is required to submit for an exemption from the requirement of 100 percent identity testing when a manufacturer petitions the Agency for such an exemption to 100 percent identity testing under 21 CFR 10.30 and the Agency grants such exemption.

    Description of Respondents: Respondents to this collection of information include manufacturers, packagers and repackagers, labelers and re-labelers, holders, distributors, warehousers, exporters, importers, large businesses, and small businesses engaged in the dietary supplement industry. Respondents are from the private sector (for-profit businesses).

    In the Federal Register of October 14, 2022 (87 FR 62429), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

    We estimate the burden of this collection of information as follows:

    Table 1—Estimated Annual Recordkeeping Burden 1

    21 CFR section; activityNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hours
    111.14; records of personnel practices, including documentation of training15,000460,000160,000
    111.23; records of physical plant sanitation practices, including pest control and water quality15,000115,0000.2 (12 minutes)3,000
    111.35; records regarding equipment and utensils, including calibration and sanitation practices400140012.55,000
    111.95; records of production and process control systems25012504511,250
    111.140; records that quality control personnel must make and keep2401,163279,1201279,120
    111.180; records associated with components, packaging, labels, and product received for packaging and labeling as a dietary supplement2401,163279,1201279,120
    111.210; requirements for what the master manufacturing record must include24012402.5600
    111.260; requirements for what the batch production record must include1451,408204,1601204,160
    111.325; records that quality control personnel must make and keep for laboratory operations1201120151,800
    111.375; records of the written procedures established for manufacturing operations26012602520
    111.430; records of the written procedures for packaging and labeling operations5015012.6630
    111.475; records of product distribution and procedures for holding and distributing operations15,000115,0000.4 (24 minutes)6,000
    111.535; records for returned dietary supplements110444013.55,940
    111.570; records regarding product complaints240600144,0000.5 (30 minutes)72,000
    Total929,140
    1  There are no capital costs or operating and maintenance costs associated with this collection of information.

    Table 2—Estimated Annual Reporting Burden 1

    21 CFR section; activityNumber of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours
    111.75; petition for exemption from 100% identity testing11188
    1  There are no capital costs or operating and maintenance costs associated with this collection of information.

    Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate. We base our estimates for the recordkeeping and reporting burdens on our experience with the recordkeeping and petition activities.

    Start Signature

    Dated: April 28, 2023.

    Lauren K. Roth,

    Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2023–09411 Filed 5–2–23; 8:45 am]

    BILLING CODE 4164–01–P

Document Information

Published:
05/03/2023
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2023-09411
Dates:
Submit written comments (including recommendations) on the collection of information by June 2, 2023.
Pages:
27898-27899 (2 pages)
Docket Numbers:
Docket No. FDA-2013-N-1619
PDF File:
2023-09411.pdf